SG11202109563WA - Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction - Google Patents
Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunctionInfo
- Publication number
- SG11202109563WA SG11202109563WA SG11202109563WA SG11202109563WA SG11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA SG 11202109563W A SG11202109563W A SG 11202109563WA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- pathway inhibitors
- chronic lung
- lung allograft
- allograft dysfunction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814085P | 2019-03-05 | 2019-03-05 | |
| PCT/US2020/021088 WO2020181034A1 (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109563WA true SG11202109563WA (en) | 2021-09-29 |
Family
ID=69941525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109563WA SG11202109563WA (en) | 2019-03-05 | 2020-03-05 | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11406640B2 (en) |
| EP (1) | EP3934651A1 (en) |
| JP (1) | JP2022524997A (en) |
| KR (1) | KR20210137087A (en) |
| CN (1) | CN114007621A (en) |
| AU (1) | AU2020232757A1 (en) |
| CA (1) | CA3132371A1 (en) |
| EA (1) | EA202192426A1 (en) |
| IL (1) | IL285999A (en) |
| MA (1) | MA55201A (en) |
| MX (1) | MX2021010545A (en) |
| SG (1) | SG11202109563WA (en) |
| WO (1) | WO2020181034A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL281146B2 (en) | 2018-09-04 | 2023-12-01 | Theravance Biopharma R& D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| AU2019335200A1 (en) | 2018-09-04 | 2021-03-11 | Theravance Biopharma R&D Ip, Llc | 5 to 7 membered heterocyclic amides as JAK inhibitors |
| JP2022506111A (en) | 2018-10-29 | 2022-01-17 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 2-Azabicyclohexane compound as a JAK inhibitor |
| US11324749B2 (en) | 2018-10-31 | 2022-05-10 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| KR20210137087A (en) | 2019-03-05 | 2021-11-17 | 인사이트 코포레이션 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| TW202144343A (en) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Crystalline hydrate of a jak inhibitor compound |
| KR20230053831A (en) | 2021-10-15 | 2023-04-24 | 주식회사 엘지에너지솔루션 | Method for fastening a welding rod and welding apparatus to which the welding rod was vertically fastened by this |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321628C (en) | 2000-06-28 | 2007-06-20 | 史密斯克莱·比奇曼公司 | Wet milling process |
| MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
| JP2009529539A (en) | 2006-03-07 | 2009-08-20 | エンダセア， インコーポレイテッド | Methods and compositions for treating respiratory disorders |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| EP3495369B1 (en) | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| EP2280701A2 (en) | 2008-04-17 | 2011-02-09 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
| EA025520B1 (en) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201802091A (en) | 2009-12-01 | 2018-01-16 | 艾伯維有限公司 | Novel tricyclic compounds |
| SI3354652T1 (en) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| RU2013120966A (en) | 2010-10-08 | 2014-11-20 | Эббви Инк. | FURO [3,2-d] Pyrimidine Compounds |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| BR112013012502A2 (en) | 2010-11-19 | 2019-03-06 | Incyte Corporation | substituted cyclobutyl pyrrolopyridine and derivative pyrrolopyrimidine derivatives as jak inhibitors |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
| UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| EA031716B1 (en) | 2012-08-17 | 2019-02-28 | Консерт Фармасьютикалс, Инк. | Deuterated baricitinib |
| SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| EA030705B1 (en) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Processes and intermediates for making a jak inhibitor |
| PE20160126A1 (en) | 2013-05-17 | 2016-02-24 | Incyte Corp | DERIVATIVES OF BIPIRAZOLE AS JAK INHIBITORS |
| ES2792549T3 (en) * | 2013-08-07 | 2020-11-11 | Incyte Corp | Sustained-release dosage forms for a JAK1 inhibitor |
| AU2014339897A1 (en) * | 2013-10-24 | 2016-04-21 | Abbvie Inc. | JAK1 selective inhibitor and uses thereof |
| CN106456773A (en) | 2014-02-28 | 2017-02-22 | 因赛特公司 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| AU2015253192B2 (en) | 2014-04-30 | 2019-05-16 | Incyte Holdings Corporation | Processes of preparing a JAK1 inhibitor and new forms thereto |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CN108349972B (en) | 2015-11-03 | 2021-06-08 | 施万生物制药研发Ip有限责任公司 | JAK kinase inhibitor compounds for the treatment of respiratory diseases |
| CN105294699B (en) * | 2015-12-04 | 2019-06-11 | 上海勋和医药科技有限公司 | Ba Rui replaces the preparation method of Buddhist nun |
| EA201990523A1 (en) * | 2016-10-03 | 2019-10-31 | NEW SELECTIVE JAK1 INHIBITORS AND THEIR APPLICATION | |
| EP3327020A1 (en) * | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
| CA2997772A1 (en) | 2017-03-09 | 2018-09-09 | Theravance Biopharma R&D Ip, Llc | Fused imidazo-piperidine jak inhibitors |
| EP3609498A1 (en) | 2017-05-01 | 2020-02-19 | Theravance Biopharma R&D IP, LLC | Methods of treatment using a jak inhibitor compound |
| AR111495A1 (en) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | FUSIONED IMIDAZO-PIPERIDINE COMPOUNDS AS JAK INHIBITORS |
| PL3746429T3 (en) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| SG11202007805SA (en) | 2018-02-16 | 2020-09-29 | Incyte Corp | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
| MX2020010815A (en) | 2018-04-13 | 2020-12-11 | Incyte Corp | Biomarkers for graft-versus-host disease. |
| US11324749B2 (en) | 2018-10-31 | 2022-05-10 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| CN113692278A (en) | 2018-12-19 | 2021-11-23 | 因赛特公司 | JAK1 pathway inhibitors for the treatment of gastrointestinal diseases |
| KR20210137087A (en) | 2019-03-05 | 2021-11-17 | 인사이트 코포레이션 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| TW202102222A (en) | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | Biomarkers for vitiligo |
-
2020
- 2020-03-05 KR KR1020217031644A patent/KR20210137087A/en unknown
- 2020-03-05 CA CA3132371A patent/CA3132371A1/en active Pending
- 2020-03-05 JP JP2021552624A patent/JP2022524997A/en active Pending
- 2020-03-05 US US16/810,045 patent/US11406640B2/en active Active
- 2020-03-05 EP EP20713496.6A patent/EP3934651A1/en active Pending
- 2020-03-05 CN CN202080024215.0A patent/CN114007621A/en active Pending
- 2020-03-05 WO PCT/US2020/021088 patent/WO2020181034A1/en active Application Filing
- 2020-03-05 SG SG11202109563WA patent/SG11202109563WA/en unknown
- 2020-03-05 AU AU2020232757A patent/AU2020232757A1/en active Pending
- 2020-03-05 EA EA202192426A patent/EA202192426A1/en unknown
- 2020-03-05 MX MX2021010545A patent/MX2021010545A/en unknown
- 2020-03-05 MA MA055201A patent/MA55201A/en unknown
-
2021
- 2021-08-31 IL IL285999A patent/IL285999A/en unknown
-
2022
- 2022-06-30 US US17/854,443 patent/US11896595B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020181034A1 (en) | 2020-09-10 |
| JP2022524997A (en) | 2022-05-11 |
| US20220331325A1 (en) | 2022-10-20 |
| AU2020232757A1 (en) | 2021-10-07 |
| CA3132371A1 (en) | 2020-09-10 |
| US20200281931A1 (en) | 2020-09-10 |
| EA202192426A1 (en) | 2021-11-15 |
| IL285999A (en) | 2021-10-31 |
| CN114007621A (en) | 2022-02-01 |
| KR20210137087A (en) | 2021-11-17 |
| MX2021010545A (en) | 2021-11-17 |
| US11406640B2 (en) | 2022-08-09 |
| EP3934651A1 (en) | 2022-01-12 |
| MA55201A (en) | 2022-01-12 |
| US11896595B2 (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285999A (en) | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | |
| IL276725A (en) | Jak1 pathway inhibitors for the treatment of cytokine-related disorders | |
| IL289534A (en) | Parp1 inhibitors | |
| IL279260A (en) | Kdm1a inhibitors for the treatment of disease | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| IL291452A (en) | Dosage forms for tyk2 inhibitors | |
| IL287902A (en) | Methods for the administration of certain vmat2 inhibitors | |
| IL284034A (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| IL290011A (en) | Ezh2 inhibition in combination therapies for the treatment of cancers | |
| ZA202101756B (en) | Medicament for the treatment of chronic cough | |
| IL287717A (en) | Substituted pyrrolopyridines as jak inhibitors | |
| IL292657A (en) | Therapeutic derivatives of interleukin-22 | |
| IL280770A (en) | Diazabicyclooctanones as inhibitors of serine beta-lactamases | |
| EP3844166C0 (en) | Substituted macrocycles useful as kinase inhibitors | |
| IL308476A (en) | Inhibitors of the menin-mll interaction | |
| IL308216A (en) | Jak1 pathway inhibitors for the treatment of prurigo nodularis | |
| IL291785A (en) | Substituted 1, 6-naphthyridine inhibitors of cdk5 | |
| IL288472A (en) | Tetracyclic compounds as cdc7 inhibitors | |
| IL281599A (en) | Tyk2 kinase inhibitors | |
| PT3510167T (en) | Methods and compositions for predicting chronic lung allograft dysfunction | |
| PT3645735T (en) | Methods and compositions for predicting chronic lung allograft dysfunction | |
| IL292690A (en) | Mrgprx2 antagonists for the treatment of inflammatory disorders | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| IL282739A (en) | Compositions and methods for the treatment of smooth muscle dysfunction | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins |